NCT07380620Enrolling by invitation
Stepwise Strategy for Treatment of Atrial Fibrillation Substrate Extended Study
Persistent Atrial Fibrillation in Southwest China Cohort Study-Stepwise Strategy for Treatment of Atrial Fibrillation Substrate Extended Study
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This is an observational, bidirectional cohort study, aiming to establish a long-term registry of adult patients with Persistent atrial fibrillation (ps-AF) in Southwest China to characterize patient profiles and evaluate embolism risk, rate control, rhythm control and complication management and outcomes over 5 years' follow-up. The objectives of the study are to: Describe the demographic, clinical, and treatment characteristics of ps-AF patients across Southwest China and assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, electrical cardioversion, catheter ablation, and left atrial appendage closure, in routine clinical practice. Identify patient- and treatment-related factors that influence therapeutic outcomes. Explore the characteristics of imaging multi-omics and blood multi-omics during follow-up. Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 28 Sept 2025
- Start date
- 9 Oct 2025
- Primary completion date
- 9 Oct 2035
- Lead sponsor
- Yuehui Yin
- Diseases
- Atrial fibrillation
- NCT number
- NCT07380620
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 9 Oct 2025 to the primary completion date, 9 Oct 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Comorbid severe hepatic/renal dysfunction or malignant tumors;
Other
- Estimated survival period \<1 year.
Who the study is looking for
- Aged ≥18 years;
- diagnosed with persistent atrial fibrillation (ps-AF), defined as episodes lasting \>7 days or requiring pharmacological/electrical cardioversion for rhythm restoration;
- Residing in Southwest China and capable of cooperating with long-term follow-up management;
- History of ps-AF treatment with complete medical records, and voluntary signing of the informed consent for long-term follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the second affiliated hospital of CQMU Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.